Ethnic delineation of primary glioblastoma genome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koo, Harim | - |
dc.contributor.author | Choi, Seung Won | - |
dc.contributor.author | Cho, Hee Jin | - |
dc.contributor.author | Lee, In-Hee | - |
dc.contributor.author | Kong, Doo-Sik | - |
dc.contributor.author | Seol, Ho Jun | - |
dc.contributor.author | Lee, Jung-Il | - |
dc.contributor.author | Choi, Jung-Won | - |
dc.contributor.author | Sa, Jason K. | - |
dc.contributor.author | Nam, Do-Hyun | - |
dc.date.accessioned | 2021-08-30T12:56:00Z | - |
dc.date.available | 2021-08-30T12:56:00Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/52608 | - |
dc.description.abstract | Glioblastoma (GBM) is the most malignant primary brain tumor in adults with substantial genomic alterations. The median survival is approximately 14.6 months, despite aggressive therapeutic intervention, which comprised of surgical resection, radiotherapy, and chemotherapy. Recent studies on cancer genomic have revealed crucial insights into dynamic molecular subgroups within GBM, which govern distinct clinical response and sensitivity of each individual to therapy. In the present study, we analyzed genomic composition of primary GBMs between two ethnic groups [IRCR (Institute of Refractory Cancer Research), and TCGA (The Cancer Genome Atlats)] to explore genomic and molecular features that constitute malignant behavior of glioblastoma based on distinct ethnicity. We identified enrichments of MAPK and p53 pathways in IRCR patients, while aberrant activation of Receptor Tyrosine Kinases (RTKs) were predominant in TCGA cohort. We also discovered differential clinical prognosis between two groups and explored essential features that present such diversity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | MUTATIONS | - |
dc.subject | LANDSCAPE | - |
dc.subject | IDH1 | - |
dc.subject | EGFR | - |
dc.subject | PROGRESSION | - |
dc.subject | EVOLUTION | - |
dc.subject | PATHWAYS | - |
dc.subject | SUBTYPES | - |
dc.subject | PDGFRA | - |
dc.subject | TUMORS | - |
dc.title | Ethnic delineation of primary glioblastoma genome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sa, Jason K. | - |
dc.identifier.doi | 10.1002/cam4.3370 | - |
dc.identifier.scopusid | 2-s2.0-85089362101 | - |
dc.identifier.wosid | 000559451100001 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, v.9, no.19, pp.7352 - 7359 | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.citation.title | CANCER MEDICINE | - |
dc.citation.volume | 9 | - |
dc.citation.number | 19 | - |
dc.citation.startPage | 7352 | - |
dc.citation.endPage | 7359 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | LANDSCAPE | - |
dc.subject.keywordPlus | IDH1 | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | EVOLUTION | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordPlus | SUBTYPES | - |
dc.subject.keywordPlus | PDGFRA | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | ethnic | - |
dc.subject.keywordAuthor | genetics | - |
dc.subject.keywordAuthor | genomics | - |
dc.subject.keywordAuthor | glioblastoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.